Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum

• Published in: International journal of hematology Vol. 107; no. 5; pp. 541 - 550
• Main Authors: Matsumura-Kimoto, Yayoi, Kuroda, Junya, Kaneko, Hitomi, Kamitsuji, Yuri, Fuchida, Shin-ichi, Nakaya, Aya, Shibayama, Hirohiko, Uoshima, Nobuhiko, Yokota, Isao, Uchiyama, Hitoji, Yagi, Hideo, Kosugi, Satoru, Matsui, Toshimitsu, Ishikawa, Jun, Matsuda, Mitsuhiro, Ohta, Kensuke, Iida, Masato, Tanaka, Hirokazu, Kobayashi, Masayuki, Wada, Katsuya, Shimazaki, Chihiro, Nomura, Shosaku, Imada, Kazunori, Hino, Masayuki, Matsumura, Itaru, Kanakura, Yuzuru, Takaori-Kondo, Akifumi
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.05.2018; Springer Nature B.V
• Subjects: Anemia; Anorexia; Bortezomib; Dexamethasone; Effectiveness; Fatigue; Fatigue failure; Hematology; Immunoglobulin G; Medicine; Medicine & Public Health; Multiple myeloma; Neutropenia; Oncology; Original Article; Patients; Steroids; Therapy; Thrombocytopenia; Toxicity; Japan; Pomalidomide; Efficacy; Adverse events; Multiple myeloma

Determinants of the efficacy and safety of pomalidomide (POM) monotherapy or POM plus dexamethasone (DEX) (POM/DEX) for relapsed and refractory multiple myeloma (RRMM) were examined retrospectively in a real-world clinical practice setting in Japan. The subjects were 108 patients registered with the...